Axicabtagene Ciloleucel for Relapsed/Refractory Large B-cell Lymphoma Following Chemoimmunotherapy

home / approval-alert / axicabtagene-ciloleucel-for-relapsed-refractory-large-b-cell-lymphoma-following-chemoimmunothera
Axicabtagene Ciloleucel for Relapsed/Refractory Large B-cell Lymphoma Following Chemoimmunotherapy

Axicabtagene Ciloleucel for Relapsed/Refractory Large B-cell Lymphoma Following Chemoimmunotherapy

Articles
FDA Grants Approval to Axi-Cel for Adults With LBCL Following First-Line Chemoimmunotherapy

FDA Grants Approval to Axi-Cel for Adults With LBCL Following First-Line Chemoimmunotherapy

April 1st 2022

Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.

Videos
Frederick Locke, MD, Speaks to Clinicians on the Use of Axi-cel in LBCL

Frederick Locke, MD, Speaks to Clinicians on the Use of Axi-cel in LBCL

April 28th 2022

Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.

Frederick Locke, MD, Reviews the Next Steps for Axi-Cel in LBCL

Frederick Locke, MD, Reviews the Next Steps for Axi-Cel in LBCL

April 21st 2022

Frederick Lock, MD, spoke about how future research regarding axicabtagene ciloleucel for patients with large B-cell lymphoma will progress.

View More >>